Article
A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults.
Antiviral therapy - 1 Jun 2023
Pierson Wim, Tuefferd Marianne, Herschke Florence, Slaets Leen, Crabbe Marjolein, Verstappen Dorien, De Pelsmaeker Steffi, Strickland Ian, Gane Edward J, Schwabe Christian, Zhang Yingjie, Meerts Peter, Vandenbossche Joris, Van Remoortere Pieter, Verbrugge Inge, De Creus An
Abstract excerpt
BACKGROUND: Chronic hepatitis B (CHB) is responsible for major disease burden worldwide. However, the number of available therapies is limited; cure remains an elusive goal. JNJ-64794964 (JNJ-4964) is an oral toll-like receptor-7 (TLR7) agonist being evaluated for the treatment of CHB. Here, we investigated the capacity of JNJ-4964 to induce transcriptomic and immune cell changes in peripheral blood in healthy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.